We are monitoring the impact of COVID-19 on MEA Chlamydia Infection Diagnostics And Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 4964
Share on
Share on

MEA Chlamydia Infection Diagnostics and Therapeutics Market Research Report – Segmented By Product Type, End User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 4964
Pages: 145

MEA Chlamydia Infection Diagnostics and Therapeutics Market Size (2021 to 2026)

The size of the Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics market is forecasted to be growing at a CAGR of 5.3% during the forecast period. The market size is predicted to grow USD 0.10 billion by 2026 from USD 0.07 billion in 2021. It captures 3% of the global market share.

The chlamydia infection diagnostics and therapeutics market in the MEA are expected to be driven by the proliferation of Chlamydia infection across the region and the increasing number of treatments of sexually transmitted diseases. Also, the Growing demand for improved diagnostic tools for pelvic inflammatory illness and signs of chlamydial infection in women at risk of tubal injury is expected to propel the market growth. In addition, the market is more likely to witness significant growth due to the rising focus on treating sexually transmitted diseases across the region.

Chlamydia trachomatis is the most commonly reported sexually transmitted infection in the world. In addition, the rate of reported chlamydia infection diagnoses continues to increase the MEA regional chlamydia market growth.

In addition, increasing funding for research and development activities, growing awareness regarding STDs in emerging countries such as South Africa, Saudi Arabia, and UAE are increasing the market growth. 

The continuous rise in the number of diagnosed chlamydia cases is due to a preference shift toward more extensive diagnostic tests, and testing of asymptomatic people with greater sensitivity, which is a shift from culture-based methods to nucleic acid amplification tests (NAATs), is more likely to expand market growth during the forecast period.

Physicians' prescription preferences for antibiotics like macrolides and tetracycline are driving the market for chlamydia infection therapies. Therefore, the macrolide sector is expected to expand at a favorable rate over the forecast period. The direct fluorescent sub-segment follows, accounting for the MEA Chlamydia Infection diagnostics market's second-largest share.

In low and middle-income countries, lack of awareness about chlamydia diagnostic tests and the shame associated with volunteer chlamydia screening can hinder market expansion. In addition, those between the ages of 16 and 25, afraid of social embarrassment, are the most likely to get chlamydia, leading to untreated or undiagnosed infections.

This research report on the MEA Chlamydia Infection Diagnostics and Therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

  • Diagnostics             
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics          
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

By End User:

  • Diagnostics             
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics          
    • Hospital Pharmacies
    • Drugstores
    • Retail Pharmacies
    • Online Pharmacies

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the MEA Chlamydia Infection Diagnostics and Therapeutics Market is the least attractive market in the global market but estimated to account for a substantial share in the global market during the forecast period. The regional market growth is attributed to the higher spending in healthcare among the people, evolving healthcare infrastructure, and Technological advancements in the healthcare sector. Besides that, favorable reimbursement policies from public and private health insurance companies and a high level of awareness among young people in developed countries in the region such as South Africa and the United Arab Emirates are driving the market for chlamydia infection diagnostics and therapeutics. The major countries such as UAE, Saudi Arabia, and South Africa significantly contribute to the MEA regional market growth. Increased chlamydia infection rates among the population, proactive governmental and private sector awareness campaigns, and improved diagnosis and treatment rates have contributed to the region's leading position in the market. Also, the increasing investments by the government and private organizations are encouraging market growth in these countries. 

KEY MARKET PLAYERS:

A few prominent companies operating in the MEA MEA Chlamydia Infection Diagnostics and Therapeutics Market profiled in this report are Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Product Type                            

                              5.1.1 Introduction           

                              5.1.2 Diagnostics             

                                             5.1.2.1 Nucleic Acid Amplification Tests (NAATs)

                                             5.1.2.2 Direct Fluorescent Tests

                                             5.1.2.3 PCR

                              5.1.3 Therapeutics          

                                             5.1.3.1 Macrolides

                                             5.1.3.2 Quinolones

                                             5.1.3.3 Sulfonamides

                                             5.1.3.4 Tetracycline

                                             5.1.3.5 Aminopenicillins

                              5.1.4 Y-o-Y Growth Analysis, By Product Type     

                              5.1.5 Market Attractiveness Analysis, By Product Type    

                              5.1.6 Market Share Analysis, By Product Type     

               5.2 End User                     

                              5.2.1 Introduction           

                              5.2.2 Diagnostics             

                                             5.2.2.1 Hospitals

                                             5.2.2.2 Specialty Clinics

                                             5.2.2.3 Diagnostic Centers

                              5.2.3 Therapeutics          

                                             5.2.3.1 Hospital Pharmacies

                                             5.2.3.2 Drugstores

                                             5.2.3.3 Retail Pharmacies

                                             5.2.3.4 Online Pharmacies

                              5.2.4 Y-o-Y Growth Analysis, By End User             

                              5.2.5 Market Attractiveness Analysis, By End User            

                              5.2.6 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Product Type

                                             6.1.3.3 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Product Type

                                             6.1.4.3 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Product Type

                                             6.1.5.3 By End User

               6.2 Middle-East                              

               6.3 Africa                          

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Bio Rad laboratories               

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Novartis AG               

               8.3 F Hoffmann-La Roche                           

               8.4 Abbott Laboratories               

               8.5 Danaher                      

               8.6 bioMerieux                

               8.7 DiaSorin SpA                             

               8.8 Siemens AG               

               8.9 Thermo Fisher Scientific                       

               8.10 Becton Dickinson and Company                     

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Diagnostics Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Diagnostics Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  8. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  9. Africa Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  10. Africa Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample